BioLingus

BioLingus is an award-winning Swiss biotechnology company and a pioneer in the research and development of oral (sublingual) and mucosal delivery of peptides and proteins. Our technology is deeply "inspired by nature," utilizing bioengineering methods to develop innovative biomimetic materials for drug delivery. We focus on treating chronic diseases such as diabetes, obesity, and inflammatory diseases through our proprietary products. BioLingus is headquartered in Switzerland, with branches in Hong Kong, China, Australia, and other regions. In terms of diabetes, we have developed "Biobetter" oral formulations of liraglutide and exenatide (GLP-1) for type II diabetes. Additionally, we are working on a combination product of insulin + GLP-1. We are also exploring the use of low-dose IL-2 for early-stage type I diabetes. Low-dose IL-2 has shown efficacy in animal models in balancing Treg and Teff immune cells to reverse or prevent type I diabetes. Furthermore, oral treatments hold even greater significance for children.